E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/6/2006 in the Prospect News Biotech Daily.

Jefferies stops Hollis-Eden coverage at hold

Jefferies & Co., Inc. analyst Adam Walsh is dropping coverage of Hollis-Eden Pharmaceuticals, Inc. with a last rating of hold and a 12- to 18-month price target of $5.50 to focus on other therapeutic areas within the biotechnology sector. Shares of the San Diego, Calif., pharmaceutical company were up 3 cents, or 0.43%, at $7.08. (Nasdaq: HEPH)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.